Crossmark

Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies

Crossref DOI link: https://doi.org/10.1007/s12325-025-03242-3

Published Online: 2025-06-04

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Douxfils, Jonathan https://orcid.org/0000-0002-7644-5298
Boretti, Emma

Beaudart, Charlotte

Dogné, Jean-Michel
License Information

Text and Data Mining valid from 2025-06-04

Version of Record valid from 2025-06-04
More Information

Article History

Received: 17 January 2025

Accepted: 12 May 2025

First Online: 4 June 2025

Declarations

:

: Jonathan Douxfils is the director and founder of Qualiblood, a contract research organization that received funding from Mithra Pharmaceuticals and Fuji Pharma. He also reports personal fees from Daiichi Sankyo, Diagnostica Stago, Gedeon Richter, Mayne, Portola, Roche and Roche Diagnostics. Emma Boretti, Charlotte Beaudart and Jean-Michel Dogné have nothing to disclose.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below